471: PSA Velocity Threshold for Predicting Prostate Cancer in Young Men with PSA &lt; 4 ng/ml

Loeb, Stacy; Roehl, Kimberly A.; Graif, Theresa; Viprakasit, Davis P.; Catàlona, William J.; Nadler, Robert B.

doi:10.1016/s0022-5347(18)32727-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSAV was originally described by Carter et al [3] who found, using a PSAV cutoff of 0.75 ng/ml/yr, a sensitivity of 72% and a specificity of 95% for prostate cancer diagnosis. Although these findings have since been confirmed by others [4,5], the optimal cutoff remains controversial, particularly at low PSA levels [4,7,8]. Contrary to these studies, others have reported that PSAV has little additional benefit over a single PSA cutoff [9][10][11].…”

Section: Introductionmentioning

confidence: 75%

Methods of Calculating Prostate-Specific Antigen Velocity

et al. 2007

View full text Add to dashboard Cite

e u r o p e a n u r o l o g y 5 2 ( 2 0 0 7 ) 1 0 4 4 -1 0 5 1 a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m Article info AbstractObjectives: Numerous methods of calculating PSA velocity (PSAV) are used and have the potential to produce differing PSAV results from the same PSA data. We calculated PSAV using three common methods and compared differences between the methods and their predictive value for prostate cancer diagnosis. Methods: From a population-based database of PSA results, men with initial PSA < 10.0 ng/ml and a subsequent diagnosis of prostate cancer or benign histology were identified. Those with !3 PSA tests before diagnosis carried out over a minimum of 18 mo were included. PSAV was calculated by using three methods:1. Arithmetic equation of change in PSA over time (AE) 2. Linear regression (LR) 3. Rate of PSA change using first and last values only (FL)The differences between the methods and test characteristics of each method were compared. Results: Of the 2204 men included, 716 (32.5%) were diagnosed with prostate cancer and 1488 (67.5%) benign histology. PSAV differed markedly in each method of calculation. The LR and FL methods had similar predictive values, which were higher than the AE method. There was strong agreement for cancer diagnosis between LR and FL (kappa = 0.85), with weaker agreement between LR/AE and FL/AE (kappa = 0.69 and 0.66, respectively). Conclusions: Methods used to calculate PSAV using the same PSA data can produce markedly different results. Linear regression should be the method of choice for calculating PSAV. Using first and last PSA values only may be adequate for everyday clinical use, as long as measurements are separated by a sufficiently long time period.

show abstract

Section: Introductionmentioning

confidence: 75%

Methods of Calculating Prostate-Specific Antigen Velocity

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Recent evidence suggests that this cut-off point is useful only for men with PSA more than4ng/ml. In younger men with a lower PSA level, PSA-V cut-off values of 0.3-0.5 ng/ml/year were suggested as a basis to perform a biopsy (22). This study demonstrated that PSA-V may improve the predictive ability of a model incorporating PSA; however, results must be interpreted with caution due to verification bias in the study design.…”

Section: Prostate Specific Antigens (Psa) Psa Isoforms and Psa Derivatementioning

confidence: 81%

Molecular markers for prostatic cancer

Castelli

Cimino²,

Magno³

et al. 2010

Front Biosci

View full text Add to dashboard Cite

Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify prognostic risk factors to early detect caP and to identify who will need active treatment. Since the introduction of prostate specific antigen (PSA), diagnosis of caP has increased even as mortality for prostatic cancer has declined. Using current recommended guidelines, the PSA test suffers from both of limited specificity and sensitivity. With the aim to improve early detection of prostatic cancer the volume adjusted PSA, PSA isoforms and PSA kinetics have been investigated. Recently, technological advances in molecular assays have led to the discovery of new markers with high specificity. Further, proteomic array profiling and DNA methylation assays could provide for more accurate diagnosis and prognosis. Current evidence suggests that no single marker is likely to achieve the desired level of diagnostic and prognostic accuracy: future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer and to predict outcomes after therapies.

show abstract

471: PSA Velocity Threshold for Predicting Prostate Cancer in Young Men with PSA < 4 ng/ml

Cited by 2 publications

References 0 publications

Methods of Calculating Prostate-Specific Antigen Velocity

Methods of Calculating Prostate-Specific Antigen Velocity

Molecular markers for prostatic cancer

Contact Info

Product

Resources

About